Clicky

Scandion Oncology A/S(SCOL)

Description: Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.


Keywords: Biotechnology Cancer Solid Tumors Treatment Of Cancer Pancreatic Cancer Colorectal Cancer Nanobiotix Debiopharm Treatment Of Colorectal Cancer

Home Page: www.scandiononcology.com

Symbion
Copenhagen, 2100
Denmark
Phone: 45 38 10 20 17


Officers

Name Title
Mr. Jan Stenvang M.S., Ph.D. Chief Scientific Officer
Dr. Francois Regis Martelet M.D. Chief Executive Officer
Mr. Johnny Stilou M.S. Chief Financial Officer
Mr. Morten Nissen General Counsel
Mr. Mads Kronborg Head of External Communication
Dr. Lars Damstrup Chief Medical Officer

Exchange: ST

Country: SE : Sweden

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0.1667
Price-to-Book MRQ: 0.5143
Price-to-Sales TTM: 233.6545
IPO Date:
Fiscal Year End: December
Full Time Employees: 4
Back to stocks